Symbols

AGEN

Agenus·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Significant Inflow of Main Funds

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AGEN

Agenus Inc.

An immuno-oncology company with a broad pipeline targeting cancer and infectious disease

Industry

Biological Technology

Established Date

Listing Date

02/04/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.agenusbio.com

Security Type

Common stock

Office address

3 Forbes Road, Lexington, Massachusetts 02421

Business

Introduction

Agenus Inc., founded in 1994, is a Delaware limited liability company. The company is a clinical-stage biotechnology company specializing in the development of therapies that activate the human immune system to fight cancer and infection. Their main clinical program is botensilimab, including monotherapy and combination therapy with balstilimab. They also have some clinical-stage immuno-oncology assets that can be used as stand-alone drugs or in combination with botensilimab and balstilimab.

Company Financials

EPS

AGEN has released its 2025 Q4 earnings. EPS was reported at -0.31, versus the expected -0.27, missing expectations. The chart below visualizes how AGEN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AGEN has released its 2025 Q4 earnings report, with revenue of 34.20M, reflecting a YoY change of 27.45%, and net profit of -10.61M, showing a YoY change of 77.33%. The Sankey diagram below clearly presents AGEN's revenue sources and cost distribution.